First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track ...
Lynk received the green light from the FDA to begin clinical trials of its investigational oral therapy LNK01006 for MS and other diseases.
Details for Remedy Plan poster presentations at the 2025 ASH Annual Meeting are as follows: ...
NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human studyCompany to present Trial in Progress ...
A next-generation drug tested in yeast was found to extend lifespan and slow aging by influencing a major growth-control pathway. Researchers also uncovered an unexpected role for agmatinases, enzymes ...
HealthDay News — Commonly used noncancer medications, including proton pump inhibitors, are associated with poorer survival and adverse events for patients with breast cancer, according to a study ...
About 40 million people worldwide are living with HIV infection. In the United Kingdom, there are approximately 100,000 people affected. If the infection is not treated, the body will eventually be ...
HIV-positive women have multiple safe birth-control options, but drug interactions, viral load and treatment stability still ...
The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...
The protein, reverse transcriptase, has become an essential tool for making DNA copies of RNA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback